Wendy Blackburn, INTOUCH SOLUTIONS
It may not be sexy but now, more than ever, marketers need to look at their analytics.
Wendy Blackburn
EXECUTIVE VICE PRESIDENT | INTOUCH SOLUTIONS
It may not be sexy but now, more than ever, marketers need to look at their analytics and optimize their programs based on results. Identify what's performing well, and where are the leaking buckets? Let go of personal favorites and shiny objects, and instead make decisions based on data. Prescription level data like that provided by Crossix can help marketers determine ROI down to the patient level. Of course, the measurability of the digital channel lends itself best to optimization, but brands really should be asking these questions across all channels. And if they're not measuring it, they should ask themselves why they are doing it at all. Here's what we're advising our clients: Now is the time to highlight the programs your company has worked hard to develop, including copay assistance, rebates, benefits investigation, trial offers, PAPs, and coupons.
Wendy Blackburn
If the medium (such as search ads) don't allow enough room for elements such as fair balance, then DDMAC is saying pharma just can't use that advertising outlet in a branded manner. I'd like to see the search engines that make millions off of pharma come up with a model that allows for fair balance. They are certainly financially incentivized to do so. And in the long run, that would be better for patients, too, because pharma wouldn't be forced into a "bait-and-switch" setup with unbranded ads leading to branded content.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
